Allurion Technologies, Inc.
Moat Score — Allurion Technologies, Inc.
Total Moat Score
9 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Allurion holds patents on its swallowable, procedureless gastric balloon design and its Iris digital monitoring platform, giving it real first-mover intellectual property in a device category with few direct copies, though it lacks FDA approval, which limits the value of that IP in the largest global market. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a sub-scale commercial-stage medtech company, Allurion has limited manufacturing scale advantages and does not benefit from meaningfully lower unit costs versus larger, better-capitalized device or pharmaceutical competitors. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Allurion can price at a premium versus older endoscopic balloons given its procedureless convenience, but pricing is increasingly constrained by competition from both legacy balloon products and, more significantly, GLP-1 drugs that are reshaping what patients and physicians are willing to pay for weight-loss interventions. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 1 / 5 | The Iris digital platform generates some data-network benefits as more patient outcomes are captured, which could improve engagement algorithms over time, but this effect is modest relative to true multi-sided network businesses. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Physicians and clinics face relatively low switching costs between weight-loss device offerings and increasingly between device-based and pharmacological approaches, limiting Allurion's ability to lock in its provider network. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The global weight-loss device and therapeutics market is enormous and does not naturally limit the number of competitors, so Allurion gains little protection from efficient-scale dynamics, especially as GLP-1 drugmakers scale production for a much larger addressable population. |